NEW ORLEANS — In a phase 2 trial, an oral PCSK9 inhibitor lowered LDL about the same amount observed with injectable PCSK9 inhibitors for 8 weeks, researchers reported at the American College of Cardiology Scientific Session.For the phase 2b, randomized, double-blind, placebo-controlled trial, researchers evaluated safety and efficacy of the oral PCSK9 inhibitor (MK-0616, Merck) in patients
MK-0616 was generally well tolerated and reduced LDL-C across all dose levels compared to placeboMerck plans to start Phase 3 pivotal study in the second half of 2023RAHWAY, N.J. (BUSINESS WIRE) $MRK #MRK Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Pha.
MK-0616, an experimental oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, met its primary endpoint and substantially reduced levels of low-density lipoprotein (LDL) cholesterol in people with high cholesterol and/or heart disease related to clogged arteries, in a study being presented at the American College of Cardiology's Annual Scientific Session Together With the World Congress of Cardiology.